Pricing Log in Create free account

BioLineRx Ltd. (BLRX) vs GT Biopharma, Inc. (GTBP)

BioLineRx Ltd. and GT Biopharma, Inc. are both Biotechnology companies. BioLineRx Ltd. and GT Biopharma, Inc. are of similar size ($9.4M and $8.8M). BioLineRx Ltd. has negative trailing earnings, so its P/E is not meaningful; GT Biopharma, Inc. trades at 0.8×. GT Biopharma, Inc. grew revenue faster over the last twelve months: −76.2% against −91.9%. GT Biopharma, Inc. has the higher net margin (0.00% vs −502.1%) and the higher return on invested capital (0.00% vs −74.3%). Across the 17 metrics below, GT Biopharma, Inc. leads on 10 and BioLineRx Ltd. on 7.

Valuation

Metric BLRX GTBP Biotechnology median
P/E n/m 0.81 10.26
P/S 5.65 121.89 9.18
P/B 0.47 2.05 2.05
Price to free cash flow n/m n/m 24.81
EV/EBITDA n/m n/m 0.65
EV/Sales 1.06 482.71 8.98
Earnings yield (90.47%) 122.77% (34.89%)
Free cash flow yield (137.86%) (194.98%) (24.52%)

Profitability

Metric BLRX GTBP Biotechnology median
Gross margin 80.03% 41.67% 65.16%
Operating margin (874.28%) 0.00% 0.00%
Net margin (502.08%) 0.00% 0.00%
Free cash flow margin (776.29%) 0.00% 0.00%
Return on equity (38.10%) 102.03% (50.12%)
Return on assets (18.21%) (176.27%) (45.60%)
Return on invested capital (74.28%) 0.00% 0.00%

Growth

Metric BLRX GTBP Biotechnology median
Revenue growth (TTM) (91.93%) (76.19%) 6.26%
EPS growth (last fiscal year) 93.72% 3.75% 29.88%
Revenue growth, 5-year CAGR — 19.67% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BLRX GTBP Biotechnology median
Debt to equity 0.40 0.00 0.00
Current ratio 1.20 2.61 4.89
Net debt to EBITDA 1.22 0.56 1.01

Dividend

Metric BLRX GTBP Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric BLRX GTBP Biotechnology median
Market cap 8.80m 9.36m 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack